Changes In Plasma Proteins And Fibrinolytic Activity In Pregnant Women In Calabar, Nigeria

M Imoru, A Emeribe

Citation

M Imoru, A Emeribe. *Changes In Plasma Proteins And Fibrinolytic Activity In Pregnant Women In Calabar, Nigeria.* The Internet Journal of Gynecology and Obstetrics. 2009 Volume 12 Number 2.

Abstract

Haemodilution and changes in various protein levels have been associated with pregnancy and in order to assess the fibrinolytic activity and changes in plasma proteins during pregnancy, 100 pregnant and 100 non – pregnant subjects (controls) of age range 18 - 40 years were studied. Standard manual techniques were used to estimate plasma fibrinogen concentration (PFC), euglobulin lysis time (ELT), total proteins and albumin. The values of PFC and ELT were $3.2\pm0.8g/l$ and 358.3 ± 84.7 minutes respectively for pregnant women as against $2.3\pm1.2g/l$ and 270.5 ± 170.6 minutes respectively for non-pregnant women and the differences were statistically significant at p<.001 and p<.001 respectively while concentrations of total proteins, albumin and globulin were $61.3\pm10.3g/l$, $38.1\pm7.4g/l$ and $19.9\pm9.1g/l$ respectively for pregnant women and $62.0\pm10.1g/l$, $38.3\pm8.0g/l$ and $21.2\pm8.1g/l$ respectively for non-pregnant women and these differences were not statistically significant (P>0.05). The differences in the values of PFC, ELT, total proteins, albumin and globulin in pregnancy with regard to the three age groups (19 – 25 years, 26 - 32 years and 33 - 39 years) were not statistically significant (P> 0.05). In conclusion, fibrinolytic activity in pregnant women differ from non – pregnant subjects due to significant increase in PFC and prolonged ELT which confirms hyperfibrinogenaemia and reduced fibrinolytic activity in this condition which therefore makes it necessary to monitor PFC and ELT in pregnancy since they are prone to thrombosis and haemorrhage.

INTRODUCTION

Fibrinolysis is a normal body process where fibrin clot, the product of coagulation is broken down by plasmin at various sites leading to the production of circulating fragments that are cleared by other proteinases or by the kidney and liver ¹⁻³.

Coagulation and fibrinolytic systems undergo major alteration during pregnancy and the knowledge of these physiological changes characterized by haemodilution, changes in the concentration of one or more plasma proteins fractions and reduced fibrinolytic activity is necessary to manage two of the more serious problems of pregnancy, haemorrhage and thrombo–embolic disease, which are caused by disorders in the mechanism of haemostasis ^{4,5}. However, the most striking maternal physiological alteration occurring during pregnancy is the increase in blood volume and this increase is needed for extra blood flow to the uterus, extra metabolic needs of the fetus and increased perfusion of other organs especially the kidneys ⁵.

Increased levels of plasma proteins and reduced fibrinolytic activity have been reported in pregnancy ^{6,7} while prolonged euglobulin lysis time and increased level of fibrinogen have

been observed by earlier authors ^{8,9}.

Since geographic and ethnic differences could influence health indices, this study was carried out in Calabar, South Eastern Nigeria to determine baseline values for plasma proteins fractions and ELT in pregnant women.

MATERIALS AND METHODS

The study was carried out between January and June, 2007 after the Ethical Committee of the University of Calabar Teaching Hospital, Calabar had approved of the study. Informed consent of each of the one-hundred (100) apparently healthy pregnant subjects who attended the antenatal clinic at the University of Calabar Teaching Hospital, Calabar and that of one hundred (100) non-pregnant subjects (controls) of similar age of 18 – 40 years drawn from Calabar metropolis was sought.

Six (6.0) ml of venous blood was withdrawn asceptically into a disposable plastic syringe from each subject and 4.5 ml of it was mixed with 0.5 ml of 31.3 g/l sodium citrate solution while the remaining 1.5ml of the blood was put in a plain bottle. Blood samples in citrated bottle were centrifuged at 2,500g for 10 minutes to separate the plasma for the determination of plasma fibrinogen concentration by dry clot weight method of Ingram¹⁰ and euglobulin lysis time by Haugie method ¹¹. The serum from the plain container was used for the determination of total proteins and albumin.

Total proteins determination using Biuret method was done by adding 1ml colour reagent to 20μ l of serum sample or standard in a test tube and the contents were mixed and incubated for 5 minutes at room temperature. The absorbance of the sample and the standard were measured against the reagent blank within 30 minutes at 540 nm while albumin concentration was determined using Randox kit by adding 3.0ml of BCG reagent (R1) to 0.01 ml distilled water, standard and serum sample respectively in three different test–tubes. The contents were mixed and colorimetric measurement of the absorbance of the sample and the standard against the reagent blank at 620nm determined.

DATA ANALYSIS

Data were expressed as mean \pm standard deviation. Students't–test and one-way analysis of variance (ANOVA) were employed and the differences of P \leq 0.05 were considered significant while correlations were determined by linear regression analysis.

RESULTS

Table 1 shows the result of plasma proteins and fibrinolytic activity in pregnant women. Significant increase in the values of PFC and ELT of 3.2 ± 0.8 g/l and 358.3 ± 84.7 minutes for pregnant women were observed when compared to 2.3 ± 1.2 g/l and 270.5 ± 170.6 minutes for non-pregnant women at P< 0.001 and P< 0.001 respectively. There were no statistically significant differences in the values of total proteins, albumin and globulin of pregnant women as compared to non-pregnant women (P> 0.05).

Table 2 shows changes in plasma proteins and fibrinolytic parameters with age during pregnancy. The differences in the values of PFC, ELT, total proteins, albumin and globulin in the three age groups (19-25 years, 26-32 years and 33-39 years) were not statistically significant (P>0.05).

Table 3 shows comparison of fibrinolytic parameters for pregnant and non-pregnant women with regard to age. Higher values of plasma fibrinogen concentration (PFC) of 3.22 ± 0.73 g/l, 3.18 ± 0.89 g/l and 3.44 ± 0.63 g/l in pregnancy were observed for the age groups 19-25 years, 26-32 years 33-39 years respectively as compared to 2.48 ± 0.67 g/l, 2.41 ± 0.5 gll and 2.5 ± 0.45 g/l for non-pregnant subjects and these differences were statistically significant at P< 0.001, P< 0.001 and P< 0.005 respectively. ELT values increased with age in pregnancy as follows: - 351.9 ± 99.6 minutes, 358.3 ± 81.7 minutes and 369.2 ± 57.0 minutes were observed for age groups 19-25 years, 26-33 years and 33-39 years respectively as compared to 261.5 ± 92.6 minutes, 290.8 ± 108.2 minutes and 245 ± 76.6 minutes for the same age groups of non-pregnant subjects. These differences were statistically significant (P< 0.001, P< 0.001 and P< 0.001 respectively).

Plasma levels of total proteins, albumin and globulin between pregnant and non-pregnant subjects with respect to age groups 19-25 years, 26-32 years and 33-39 years were not statistically significant (P> 0.05).

Figure 1

Table 1:CHANGES IN PLASMA PROTEINS AND FIBRINOLYTIC ACTIVITY IN PREGNANT WOMEN

Parameter	Pregnant Women	Non-pregnant	P-value	
	(n = 100)	Women (n = 100)		
PFC (g/l)	3.2 ± 0.8	2.3 ± 1.2	<0.001	
ELT (mins)	358.3 ± 84.7	270.5 ± 170.6	<0.001	
Total proteins (g/l)	61.3 ± 10.3	62.0 ± 10.1	>0.05	
Albumin (g/l)	38.1 ± 7.4	38.3 ± 8.0	>0.05	
Globulin (g/l)	19.9 ± 9.1	21.2 ± 8.1	>0.05	

Figure 2

Table 2: CHANGES IN PLASMA PROTEINS AND FIBRINOLYTIC PARAMETERS IN PREGNANT WOMEN IN RELATION TO AGE

19-25 years	26-32 years	33-39 years	P-value	
(n = 27)	(n = 57)	(n =16)		
3.22 ± 0.73	3.18 ± 0.89	3.44 ± 0.63	>0.05	
351.9 ± 99.6	358.3 ± 81.7	369.2 ± 57.0	>0.05	
61.2 ± 10.9	61.6±8.9	60.3 ± 14.4	>0.05	
37.6 ± 6.9	38.1 ± 7.4	39.2 ± 8.8	>0.05	
20.4 ± 8.4	20.3 ± 9.1	17.7 ± 10.1	>0.05	
	(n = 27) 3.22 ± 0.73 351.9 ± 99.6 61.2 ± 10.9 37.6 ± 6.9	$(n = 27)$ $(n = 57)$ 3.22 ± 0.73 3.18 ± 0.89 351.9 ± 99.6 358.3 ± 81.7 61.2 ± 10.9 61.6 ± 8.9 37.6 ± 6.9 38.1 ± 7.4	$(n = 27)$ $(n = 57)$ $(n = 16)$ 3.22 ± 0.73 3.18 ± 0.89 3.44 ± 0.63 351.9 ± 99.6 358.3 ± 81.7 369.2 ± 57.0 61.2 ± 10.9 61.6 ± 8.9 60.3 ± 14.4 37.6 ± 6.9 38.1 ± 7.4 39.2 ± 8.8	

Figure 3

Table 3: PLASMA PROTEINS AND FIBRINOLYTIC PARAMETERS OF PREGNANT AND NON-PREGNANT WOMEN WITH REGARD TO AGE

19-25 years		26-32 years		33-39 years	
Pregnant	Non- pregnant	Pregnant	Non- pregnant	Pregnant	Non- pregnant
27	60	57	34	16	6
3.22 ± 0.73	2.48 ± 0.67*	3.18 ± 0.89	2.41±0.5*	3.44 ± 0.63	2.5 ± 0.45**
351.9±99.6	261.5 ± 92.6*	358.3±81.7	290.8± 108.2*	369.2±57.0	245 ± 76.6*
61.2 ± 10.9	61.7 ± 11.9 n s	61.6 ± 8.9	62.1±6.4 n s	60.3 ± 14.4	63.7 ± 8.2 n s
37.6 ± 6.9	37.5 ± 9.0 n.s	38.1 ± 7.4	39.4 ± 6.6 n s	39.2 ± 8.8	40.1 ± 3.3 n s
20.4 ± 8.4	21.8 ± 8.8	20.3 ± 9.1	20.2 ± 6.1	17.7 ± 10.1	21.1 ± 6.7
	Pregnant 27 3.22 ± 0.73 351.9 ± 99.6 61.2 ± 10.9 37.6 ± 6.9	Pregnant Non-pregnant 27 60 3.22 ± 0.73 2.48 ± 0.67* 351.9 ± 99.6 261.5 ± 92.6* 61.2 ± 10.9 61.7 ± 11.9 ns 37.6 ± 6.9 37.5 ± 9.0 ns	Pregnant Non-pregnant Pregnant 27 60 57 3.22 ± 0.73 2.48 ± 0.67* 3.18 ± 0.89 351.9 ± 99.6 261.5 ± 92.6* 358.3 ± 81.7 61.2 ± 10.9 61.7 ± 11.9 61.6 ± 8.9 ns 37.6 ± 6.9 37.5 ± 9.0 35.1 ± 7.4	Pregnant Non- pregnant Pregnant Non- pregnant 27 60 57 34 3.22 ± 0.75 2.48 ± 0.67* 3.18 ± 0.89 2.41± 0.5* 351.9 ± 99.6 261.5 ± 92.6* 358.3 ± 81.7 290.8 ± 108.2* 61.2 ± 10.9 61.7 ± 11.9 61.6 ± 8.9 62.1± 64 ns ns ns 35.1 ± 7.4 37.6 ± 6.9 37.5 ± 9.0 35.1 ± 7.4 39.4 ± 6.6	Pregnant Non- pregnant Pregnant Non- pregnant Pregnant 27 60 57 34 16 3.22 ± 0.73 2.48 ± 0.67* 3.18 ± 0.89 2.41 ± 0.5* 3.44 ± 0.63 351.9 ± 99.6 261.5 ± 92.6* 358.3 ± 81.7 290.8 ± 369.2 ± 57.0 61.2 ± 10.9 61.7 ± 11.9 61.6 ± 8.9 62.1 ± 6.4 60.3 ± 14.4 n s n s n s n s 39.4 ± 6.6 39.2 ± 8.8 37.6 ± 6.9 37.5 ± 9.0 38.1 ± 7.4 39.4 ± 6.6 39.2 ± 8.8 n s

Values are expressed in mean \pm SD

- ns = not significant (P> 0.05)
- * = significant (P<0.001) compared to non pregnant subjects with age</p>

** = significant (P<0.005) compared to non-pregnant subjects with age

DISCUSSION

Haemodilution and changes in various protein levels have been observed during pregnancy and the knowledge of these physiological changes is necessary to manage problems of haemorrhage and thrombo-embolism associated with the condition.

Reports from different parts of the world showed that there is hyperfibrinogenaemia in pregnant women ¹²⁻¹⁴ and this common finding from different authors has been confirmed in this study. The increased concentration of fibrinogen could be due to enhanced synthesis and utilization in the utero-placental circulation or hormonal changes, particularly high levels of estrogen ⁵.

The present study further showed that there was prolonged ELT during pregnancy which is associated with reduced fibrinolytic activity. Suppression of fibrinolytic activity has been found to play an important role in the prevention of haemorrhage during pregnancy ¹⁵.

Total proteins, albumin and globulin concentrations in pregnancy showed no significant differences when compared to non-pregnant subjects . These findings are comparable to earlier authors ^{13,16,17}, however, changes in the concentration one or more of the plasma proteins could lead to change in plasma viscosity which plays role in haemorheology ¹⁸.

The study showed that age had no significant effect on PFC,

ELT, total proteins, albumin and globulin in pregnant women. However, pregnancy significantly increased the values of PFC and ELT while the concentrations of total proteins, albumin and globulin showed no significant differences irrespective of age.

In conclusion, this study has shown that fibrinolytic activity in pregnant women differ from non-pregnant subjects due to significant increase in PFC and prolonged ELT which confirms hyperfibrinogenaemia and reduced fibrinolytic activity in pregnancy.

It is recommended that PFC and ELT should be monitored in pregnancy especially when there is risk of thrombotic crisis.

References

1. Walker JB, Neshein ME. The molecular weights, mass distribution, chain composition and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. Journal of Biological Chemistry 1999; 274: 5201-12.

2. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. British Journal of Haematology 2005 ;129: 307-21.

3. William M. Primary or Secondary fibrinolysis. Verimed Healthcare Network. Available at: http:

//www.umm.edu/ency/article/000577.htm. Accessed January 26th 2007.

4. Bonnar J. Haemostasis and coagulation disorders in pregnancy. In Bloom AL, Thomas DP, editors. Haemostasis and thrombosis, 1st ed. London: Churchill Livingstone; 1981. p. 454-71.

5. Koos JB, Moore JP. Maternal physiology during pregnancy. In Alan HD, Lauren N editors. Current obstetric and gynaecologic diagnosis and treatment, 9th ed. New York: Mc Graw Hill Companies; 2003. p. 154-62.
6. Tommaso MD, Ferretti C, Conforti D, et al. Haematocrit and haemoglobin parameters of hematic viscosity in pregnancy-induced hypertension. Minerva Ginecologica 1991;43(5):237-40.

7. Benneth B, Moore NR, Cruickshank DJ, et al. Plasminogen activator inhibitors (PAI – 1) and (PAI – 2) in normal pregnancies pre – eclampsia and hydatidiformn mole. British Journal of Obstertrics and Gynaecology 1993; 100: 370 – 74.

 Akinsete I, Uyanwah PO. The fibrinolytic enzymes system in pregnancy in Nigerians. African Journal of Medicine and Medical Sciences 1989; 18(2): 89-93.
 Adediran IA, Durosinmi,MA, Oguniyi SO, et al. Haemostatic parameters in normal pregnant Nigerians and Nigerians with hypertensive disorders of pregnancy. The Nigerian postgraduate Medical Journal 1999; 49-52.
 Ingram GIC. A suggested schedule for the rapid investigation of acute haemostatic failure. Journal of Clinical Pathology 1961; 14: 156-60.
 Haugie C. Euglobulin lysis time (method). In William JW, Benller E, Ersley AJ, et al, editors. Haematology, 3rd ed. Singapore: MC Graw – Hill Books 1986. p. 1670-78.
 Wright JG, Cooper P, Astedt B, et al. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and

inhibitors and the euglobulin clot lysis time. British Journal

of Haematology 1988; 69(2): 253-58. 13. Kametas N, Krampl E, Mcauliffe F, et al.

Haemorrheological adaptation during pregnancy in a Latin American population. European Journal of Haematology 2001; 66(5): 305-11.

14. Salawu L, Durosinmi MA. Erythrocyte rate and plasma viscosity in health and disease .Nigerian Journal of Medicine 2001; 10(1): 11-13.

15. Yousif S, Malgorzata P, Maciej S, et al. Expression of urokinase plasminogen activator, its receptor and

plasminogen activator inhibitor in the plasma of pathological pregnant women. The Internet Journal of Gynaecology and

Obstetrics 2005; Volume 5, number 1.

16. Ubero-Fernandez J, Puertas-Prieto A, Valenzuela-Ruiz A, et al. Lipoproteins in pregnant women before and during delivery; Influence on neonatal haemorrheology. Journal of

Clinical Pathology 1996; 49(2): 120-133. 17. Choi JW, Pai SH. Tissue plasminogen activator levels change with plasma fibrinogen concentrations during pregnancy. Annals of Haematology 2002; 81 (11): 611-615.

18. Harkness, J. (1971). The viscosity of human plasma; its measurement in health and disease. Biorheology 1971; 8: 171-193.

Author Information

M. Imoru, FMLSCN, MSc Department Of Haematology And Blood Transfusion, Aminu Kano Teaching Hospital

A.O. Emeribe, FMLSCN, PhD

Haematology Unit, Faculty Of Allied Medical Sciences, University Of Calabar